AffyImmune is a development stage biotechnology company focused on creating technologies that expand the utility and improve the safety of cell-based immunotherapy for cancer.
AffyImmune’s core focus is on developing CAR T cells effective in treating solid tumors, which account for 90% of all cancer fatalities.
An IND for a Phase I clinical trial of our lead compound in patients with anaplastic or refractory thyroid cancer has been approved by the FDA.
AffyImmune was founded in 2016 on the basis of research and technologies developed at Harvard Medical School and Weill Cornell Medical College.


Scientific Advisory Board


AffyImmune Therapeutics is actively seeking partnerships to advance both its pipeline of products and technology development initiatives. If you are interested in partnering with us, please contact us

Partner with Us

Our Partners